

Table 1: Characteristics of included trials

Study	Location (number of sites)	Control group size (n)	Control group mortality (95% CI)	NE required for enrollment ^a	Mean/median NE on enrollment ^a	Patients receiving multiple vasopressors	Mean/median NE equivalents on enrollment ^a
Annane et al., 2007	France (19)	169	34% (27-41%)	Any dose	Not reported	8.3% (14/169)	Not reported
Annane et al., 2010	France (11)	254	39% (33-45%)	Any dose	0.5	Not reported	0.5
Annane et al., 2013	France (24)	203	35% (28-41%)	0.25	Not reported	0% (0/203)	Not reported
Annane et al., 2018	France (34)	627	39% (35-43%)	0.25	Not reported	9.3% (58/627)	Not reported
Asfar et al., 2014	France (29)	388	34% (29-39%)	0.1	Not reported	5.2% (20/388)	Not reported
Bahloul et al., 2012	Tunisia (1)	26	46% (29-65%)	Any dose	0.4	Not reported	0.4
Chen et al., 2015	USA (1)	41	42% (28-57%)	Any dose	0.9	Not reported	0.9
Cicarelli et al., 2007	Brazil (1)	15	80% (55-93%)	Any dose	Not reported	Not reported	Not reported
Donnino et al., 2016	USA (2)	45	44% (31-59%)	Any dose	0.33	Not reported	0.33
Gordon et al., 2014	United Kingdom (4)	30	23% (12-41%)	Any dose	0.37	73.3% (22/30)	0.31
Gordon et al., 2016	United Kingdom (18)	103	26% (19-35%)	Any dose	0.18	Not reported	0.18
Hjortrup et al., 2016	Scandinavia (9)	76	32% (22-43%)	Any dose	0.38	Not reported	0.38
Morelli et al., 2007	Italy (1)	10	40% (17-69%)	0.5	Not reported	0% (0/10)	Not reported
Morelli et al., 2008	Italy (1)	16	56% (33-77%)	Any dose	Not reported	0% (0/16)	Not reported
Morelli et al., 2008	Italy (1)	20	65% (43-82%)	0.9	0.2	0% (0/20)	0.2
Morelli et al., 2010	Italy (1)	20	70% (48-85%)	Any dose	0.4	Not reported	0.4
Morelli et al., 2013	Italy (1)	77	81% (70-88%)	Any dose	0.65	Not reported	0.69
Ngaosuwan et al., 2017	Thailand (1)	36	50% (34-66%)	Any dose	0.16	Not reported	0.16
Patel et al., 2010	USA (1)	118	43% (35-52%)	Any dose	0.41	Not reported	0.44
Payen et al., 2015	France (18)	113	20% (13-28%)	Any dose	Not reported	8.0% (9/113)	Not reported
Puskarich et al., 2014	USA (1)	15	60% (36-80%)	Any dose	Not reported	Not reported	Not reported
Ranieri et al., 2012	5 continents (208)	834	24% (21-27%)	0.07	1.12	Not reported	1.07
Russell et al., 2008	Canada, Australia, USA (27)	382	39% (34-44%)	0.07	Not reported	29.1% (111/382)	Not reported
Russell et al., 2017	Belgium, Denmark, USA (16)	21	19% (8-40%)	0.1	0.28	0% (0/21)	0.26
Schmoelz et al., 2006	Germany (1)	20	35% (18-57%)	0.05	0.35	Not reported	0.34
Schortgen et al., 2012	France (7)	99	40% (31-50%)	Any dose	1.14	5.1% (5/99)	1.16
Shum H et al., 2014	Hong Kong (1)	8	13% (2-47%)	0.2	0.3	Not reported	0.29
Venkatesh et al., 2018	3 continents (69)	1860	24% (22-26%)	Any dose	0.4	30.6% (569/1860)	0.43

^aNorepinephrine doses in µg/kg/min

Abbreviations: NE: Norepinephrine